We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+3.29%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.76B
AUM Growth
+$170M
Cap. Flow
+$156M
Cap. Flow %
5.64%
Top 10 Hldgs %
29.4%
Holding
140
New
9
Increased
43
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$48.9M
2
ADPT icon
Adaptive Biotechnologies
ADPT
+$26.6M
3
PODD icon
Insulet
PODD
+$25.1M
4
CHRS icon
Coherus Oncology
CHRS
+$21M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$14.7M

Top Sells

Rank Stock Value
1
WMGI
Wright Medical Group Inc
WMGI
+$29M
2
CVET
Covetrus, Inc. Common Stock
CVET
+$17.8M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$16.4M
4
IFRX icon
InflaRx
IFRX
+$8.5M
5
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$7.18M

Sector Composition

Rank Sector Weight
1 Healthcare 86.18%
2 Consumer Staples 0.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RDUS
26
DELISTED
Radius Health, Inc.
RDUS
$30.4M 1.1%
1,250,000
+75,000
+6% +$1.64M
MOH icon
27
Molina Healthcare
MOH
$10.3B
$29.5M 1.07%
206,000
-1,500
-0.7% -$205K
PODD icon
28
Insulet
PODD
$9.79B
$29.2M 1.06%
+244,500
New +$25.1M
MDCO
29
DELISTED
Medicines Co
MDCO
$29.2M 1.06%
800,000
+70,600
+10% +$2.3M
BPMC
30
DELISTED
Blueprint Medicines
BPMC
$29M 1.05%
307,500
+32,500
+12% +$2.68M
ADPT icon
31
Adaptive Biotechnologies
ADPT
$3.97B
$29M 1.05%
+600,000
New +$26.6M
ALGN icon
32
Align Technology
ALGN
$12.3B
$28.7M 1.04%
105,000
– –
CI icon
33
Cigna
CI
$74.6B
$28.7M 1.04%
182,300
+92,300
+103% +$14.5M
PTLA
34
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$27.3M 0.99%
1,008,000
+133,000
+15% +$4.17M
MDGL icon
35
Madrigal Pharmaceuticals
MDGL
$11.8B
$26.9M 0.97%
256,900
+1,650
+0.6% +$177K
ONC
36
BeOne Medicines Ltd
ONC
$39.4B
$26.6M 0.96%
214,800
– –
INCY icon
37
Incyte
INCY
$24.4B
$26.5M 0.96%
312,300
– –
NVTA
38
DELISTED
Invitae Corporation
NVTA
$26.4M 0.96%
1,125,000
-25,000
-2% -$532K
ARGX icon
39
argenx
ARGX
$54.1B
$25.7M 0.93%
181,700
– –
BAX icon
40
Baxter International
BAX
$14.2B
$24.6M 0.89%
300,700
– –
ASND icon
41
Ascendis Pharma A/S
ASND
$16.8B
$24.6M 0.89%
213,500
– –
RARX
42
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$24.2M 0.87%
804,000
– –
PRAH
43
DELISTED
PRA Health Sciences, Inc.
PRAH
$23.8M 0.86%
240,000
– –
TMO icon
44
Thermo Fisher Scientific
TMO
$220B
$23.8M 0.86%
81,000
– –
ALNY icon
45
Alnylam Pharmaceuticals
ALNY
$29.3B
$23.8M 0.86%
327,700
+94,200
+40% +$7.23M
EPZM
46
DELISTED
Epizyme, Inc
EPZM
$23.2M 0.84%
1,850,100
+96,725
+6% +$1.24M
BIIB icon
47
CALL
Biogen
BIIB
$30.7B
$22.8M 0.82%
97,500
– –
INSM icon
48
Insmed
INSM
$28.6B
$22.8M 0.82%
890,000
+40,000
+5% +$1.11M
LKFT
49
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
$21.3M 0.77%
165,000
– –
MRTX
50
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$20.9M 0.75%
202,500
+22,500
+13% +$1.75M
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, Rock Springs Capital Management held 140 positions worth $2.76B, up 6.6% from $2.59B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rock Springs Capital Management deployed $156M of net new capital in Q2 2019, opening 9 new positions and adding to 43 existing holdings. Its largest new stake was Bristol-Myers Squibb: 1,050,000 shares worth $47.6M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 85% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was Covetrus, Inc. Common Stock, an estimated $17.8M trimmed.

  • Rock Springs Capital Management's largest Q2 2019 buy was Bristol-Myers Squibb: 1,050,000 shares worth $47.6M.
  • Rock Springs Capital Management added most to Coherus Oncology in Q2 2019, an estimated $21M increase.
  • Rock Springs Capital Management's biggest Q2 2019 reduction was Covetrus, Inc. Common Stock, cutting an estimated $17.8M.
  • Rock Springs Capital Management fully exited Wright Medical Group Inc in Q2 2019, selling an estimated $29M.
  • Rock Springs Capital Management's ten largest holdings make up 29% of its $2.76B portfolio in Q2 2019.
  • Rock Springs Capital Management opened 9 new positions and closed 5 in Q2 2019.
  • Rock Springs Capital Management's portfolio value rose 6.6% quarter-over-quarter to $2.76B.

Based on Rock Springs Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.